

C677T METHYLENETETRAHYDROFOLATE REDUCTASE HOMOZYGOSIS AND VITAMIN SUPPLEMENT IN MIGRAINEUR CHILDREN

PURPOSE: Methylenetetrahydrofolate reductase (MTHFR) variant C677T has been associated with an increased genetic risk in migraine susceptibility. Individuals with the homozygous genotype show higher levels of plasma homocysteine (Hcy). [7,17,21]

METHODS: Open-label study evaluating clinical trial was performed on 148 children migraineurs among 236 children suffering from headache, admitted to the Headache Regional Centre in l'Aquila (Italy)-Neuropsychiatric clinic, recruited and observed sequentially during the years 2015-2017. 31 patients (16,6% of all the sample) MTHFR homozygous were selected and underwent clinical evaluation of migraine characteristics (frequency, severity of pain and use of acute treatment) at baseline and after a 12 month-period of daily supplement of vitamins B9(2 mg), B6(25 mg), B12(400 mcg). In 20 patients with hyper Hcy (>95°percentile for age) the second collection of blood sample was obtained for Hcy assessment. Diagnosis of headache according to ICHD-III criteria. Statistical analysis is made by Wilcoxon test.

RESULTS: 20 children suffer from Migraine without aura (MwoA) and 11 from Migraine with aura (MA). 86% of children aged >10 years had significantly higher Hcy values compared with controls ($p<0.0001$). 21 patients (70%), 14 F and 7 M (13 MwoA and 8 MA), have Hcy values > 95°percentile. In all the sample the vitamin supplementation was effective in producing significant reduction in Hcy levels ($p=0.0001$) and a significant improvement of migraine disability of frequency ($p<0.0001$), severity of pain ($p<0.0003$) and use of acute treatment ($p<0.0001$).

CONCLUSIONS: The study results are encouraging and emphasize the importance of a comprehensive therapy in paediatric migraines.

KEYWORDS: Headache, Children, Genetic, Homocysteine

INTRODUCTION

Migraine is an extremely debilitating and highly prevalent neurovascular disorder presenting multiple symptoms. The methylenetetrahydrofolate reductase (MTHFR) gene variant C677T has been implicated as a genetic risk factor in migraine susceptibility, particularly in Migraine with Aura (MA) [16,28,32]. The MTHFR gene is located on chromosome 1p36.3 and encodes for a key enzyme for the metabolism of folate and homocysteine[6]. C677T polymorphism is characterized by a substitution of an alanine with a valine at position 222; this substitution leads to a reduction on enzyme activity [1,14]. Subjects with the C677T variant present reduced capacity to remethylate Homocystein to methionine, these conditions increase Homocystein plasma levels [14]. Individuals with the homozygous (TT) state for this mutation showed higher levels of plasma homocysteine [6]. Homocysteine acts as an excitatory amino acid and may influence the threshold for migraine headache. High levels of homocysteine are associated with vascular and endothelial damage and with cerebrovascular and cardiovascular disease; in particular, it has been assumed that hyperhomocysteinemia is involved in reducing brain blood flow and producing the depolarization wave defined as CSD [19]. These facts associated with reduced oxygen transfer could act as trigger of migraine attack. The endothelial damage induced by high levels of homocysteine could decrease nitric oxide release and leads to the initiation and maintenance of migraine attacks [22]. High homocysteine levels are seen in individuals with migraine with aura [26,33]. A poor number of studies have found a significant association between the TT genotype and migraine [24,7]; especially MA [17] inconsistently [1,27]. The MTHFR C677T polymorphism has been reported to be associated with migraine and depression [5]; while other studies failed to show this association. Our results in previous study confirmed available data of literature [32]. In fact, the migraineurs had higher prevalence of MTHFR mutation, especially in homozygous with respect to tension type headache [27,33]. According to Lea [15] and other Authors [14,24], C677T MTHFR variant predisposes to a susceptibility to migraine with aura and not to that without aura, in particular, it is well- known for European Caucasian population. A meta-analysis of 15 case control studies showed a close correlation between TT variant and Caucasians suffering from MA, in non Caucasian population this genotype is associated with total migraine. The C677T allele (rs1801133), a common variant of the MTHFR gene has a frequency of approximately 23-41% in the

Caucasian population [2,6,13].The data of Italy population show mutation in homozygous in 8, 8-10% of people [26]. Many authors have demonstred that the Migraine with and without aura (MA and MwoA) have many diagnostic characteristics in common but in children aren't studies controlled of large study samples [14,21]. Individuals homozygous for this variant express approximately 30% of the mean activity of MTHFR enzyme levels, as compared with individuals without the substitution allele. Aim of this study is to verify if the homozygous genotype of allele CT of MTHFR determine the clinical variants of Migraine with and without aura (MwoA and MA) and if supplement of vitamin complex of VitB9, Vit B6 and Vit B12 effects the improvement of headache as intensity as frequency of attacks. [14,18]

METHODS

The study population was enrolled in the Department of Neuropsychiatric afferring to Regional Headache Center of Region Abruzzo, University of L'Aquila. The patients were recruited according to temporal criteria by observations sequentially during the years 2015 and 2016 and 2017. The children are born in Italy from parents italians. The diagnosis of headache was made according to ICHD-III criteria [11]. The sample of study consists of 236 patients, 121 females and 115 males, aged between 8 to 13 years. We considered 148 Migraineurs. Whole blood samples were collected using EDTA tubes and transferred in an upright position to local lab, where were stored at -20°C to freezer. During patient diagnostic evaluation we detected C677T variant of MTHFR based on the Real-Time Polymerase Chain Reaction (RT-PCR), we considered the homozygous and heterozygous genotype for T allele. The polymorphism C677T was identified using SAMPLE PREP thrombo kit (Diatech Pharmacogenetics), using a TAQ man probe and a melting analysis to determinate genotypes [6]. The total homocysteine (tHcY) was determinate using a chemiluminescent immunoenzymatic assay (CMIA) homocysteine Architect [25]. 31patients, aging from 6 to 17 years, 11 Males and 20 Females, with MTHFR homozygous genotype, were selected and underwent clinical evaluation of migraine characteristics. The following migraine parameters were considered: headache frequency expressed as number of days by month, pain intensity with the VAS scale (0-10) and use of drugs (number of administrations for month) at baseline and after a 12 month-period of daily supplement of vitamins B9(2 mg), B6(25 mg), B12(400 mcg) and homocysteine values. We compared homocysteine values to normal values found in a

control sample of 30 children of same age and compared to literature data in a school age population [4]. Furthermore, homocysteine values were compared with those of heterozygous subjects. Clinical and laboratory data were divided according to the diagnosis of migraine. In 20 children suffer from MwoA and 11 from MA with **iperHcyA** (>95° percentile for age) the second collection of blood sample was obtained for Hcy assessment. Diagnosis of headache was made according to ICHD-III criteria. Informed consent was obtained for participation in the study by the parents of the children. For the comparison of data referring to the characteristics of the headache (frequency, pain and use of the drugs) a repeated measures **ANOVA on log-transformed** data. Statistical analysis is made by Wilcoxon test (ANOVA).

RESULTS

96 patients are suffering from **Migraine without Aura (MwoA)**, 39 from **Migraine with aura (MA)**, 13 from chronic migraine. The heterozygous genotype was present in 88% of sample, 50 (56%) females and 47 (60%) males, whereas the homozygous genotype in 31 patients (16,6%), 19 females and 12 males. Table 1 summarizes the clinical data of each of 31 patients homozygous type at time 0 and after 12 months of follow up. The diagnosis of headache, according to ICHD-III beta version 2013, is Chronic migraine in 11 pt, MwoA in 9 pt and MA in 11 patients. The vitamins supplement is efficacy to reduce values of homocysteine and to improve frequency, pain and disability of migraine. Figure 1 shows the results of statistical processing of frequency of headache. In fact the chronic type of migraine disappears and the intensity of pain is reduced by 80 percent of the cases. In Figure 2 there are the results of pain intensity and in Figure 3 the results of drug use of the whole sample, pre and post vitamins treatment.




Fig.1 Frequency of Migraine* attacks Pre-Post Vitamins treatment ($p<0.0001$). *Migraine diagnosis. 1: MwoA; 2: MA




Fig.2 Pain of Migraine*attacks Pre-Post Vitamins treatment ($p<0.0003$). *Migraine diagnosis. 1: MwoA; 2: MA




Fig.3 Drugs of Migraine*attacks Pre-Post Vitamins treatment ($p<0.0001$). *Migraine diagnosis. 1: MwoA; 2: MA

There is a very significant difference in all parameters considered after 12 months of follow-up, while there is no difference in behaviour between the 2 types of migraine. The homocysteine values of all the sample is summarized in Figure 4. Values are grouped according to the age of the children (>10 < 10 years). It is noted that homozygous homocysteine values increase with age, unlike controls in which the increase with age is poor. 21 patients (70%), 14 females and 7 males have Hcy values >95° percentile. The values over 95° for age and the mean and SD compared to normal controls are $12,62 \pm 6,86$ ($\mu\text{M/l}$) vs $5,41 \pm 1,17$ ($p<0,001$).




Fig.4 Homocysteine values of all the sample on the basis of age

Patients	Age	Sex	Migraine Diagnosis	Frequency		Pain Severity*		Drugs	
				Pre	Post	Pre	Post	Pre	Post
1.	7	F	MwoA	3	2	2	2	2	1
2.	8,1	F	MA	17	7	3	2	10	4
3.	16,8	F	MwoA	15	10	2	1	9	3
4.	7,3	F	MwoA	6	4	2	2	4	2
5.	8,6	M	MwoA	20	11	3	1	11	5
6.	8,1	M	MwoA	18	5	3	2	3	0
7.	8,1	M	MwoA	11	6	1	1	2	0
8.	15,2	F	MwoA	13	5	2	2	3	0
9.	17,1	F	MA	4	2	2	2	4	1
10.	15,7	F	MA	5	2	3	1	3	0
11.	9,11	M	MwoA	3	1	4	3	3	0
12.	10,6	M	MwoA	14	5	3	2	7	0
13.	17,9	F	MwoA	7	4	3	3	5	3
14.	8,11	F	MA	20	8	2	2	12	6
15.	10	M	MwoA	5	4	2	2	4	1
16.	15,7	F	MwoA	11	4	2	2	5	3
17.	9,05	F	MwoA	16	4	3	2	9	0
18.	12,8	F	MwoA	7	2	2	2	5	2
19.	16,6	M	MA	8	5	2	1	7	0
20.	12,1	F	MwoA	2	1	2	2	2	1
21.	11,1	M	MwoA	5	2	2	2	3	0
22.	4,5	F	MA	4	2	2	1	3	0
23.	6,5	F	MwoA	3	1	2	2	2	0
24.	14,6	F	MwoA	17	2	3	2	7	0
25.	16,3	F	MA	2	1	3	2	1	0
26.	13,7	M	MwoA	21	11	3	1	9	2
27.	15,9	M	MA	12	7	2	1	7	4
28.	12,2	M	MA	19	8	2	3	13	4
29.	14	F	MwoA	16	7	3	3	12	3
30.	8	F	MA	16	7	2	3	9	2
31.	8,6	F	MA	8	4	4	4	0	0

Tab.1 Clinical data of each patient at time 0 and after 12 months of follow up.

*Pain Severity. 1: low, 2: mild, 3: high, 4: very-high.

Among the cohort of children with hyperhomocysteinemia the diagnosis are: MwoA in 13 and MA in 8 patients. The values of Hcy after 12 months of vitamin supplement are reduced in the normal range for age. In all the sample the vitamin supplementation was effective in producing significant reduction in Hcy levels ($p=0.0001$)(Fig.5) and a significant improvement of migraine disability in terms of frequency ($p<0.0001$)(Fig.1), severity of pain ($p<0.0003$)(Fig.2) and use of acute treatment ($p<0.0001$)(Fig.3).




Fig.5 Values of Hcy after 12 months of Vitamin supplement($p=0.0001$)

DISCUSSION

Our data show that the heterozygous genotype was presented in 88% of migraineurs whereas the homozygous genotype in 16,6% of patients. Higher values than the general population, as already demonstrated in a previous study [32]. The data of Italy population show mutation in homozygous in 8,8-10% of people [26]. The observational literature suggests a consistent relationship between aspects of brain function and folate/B12 and/or homocysteine, a huge research effort predicated on the hypothesis that supplementation with these vitamins should decrease homocysteine levels and thereby either improve cognitive function or attenuate cognitive decline and the risk of dementia has generated largely equivocal results [3,13,19]. Indeed, reviews and meta-analyses published over more than a decade have provided scant evidence to support this hypothesis [8,14,20,31,34]. Reasons for hyperhomocysteinemia may include mutations in homocysteine metabolizing genes such as MTHFR, Methionine synthase reductase (MTRR), and cystathionin beta synthase (CBS), or possible nutritional deficiencies in cofactors involved in homocysteine metabolism. Folate is needed to drive the

methionine synthesis pathway, as a lack of dietary folate and/or reduced MTHFR enzymatic activity can result in increased homocysteine levels in blood plasma. Hyperhomocysteinemia is caused by abnormal methionine biosynthesis due to deficiencies in folate, vitamin B12, and vitamin B6 [30]. High levels of homocysteine are associated with vascular and endothelial damage and with cerebrovascular and cardiovascular disease; in particular, it has been assumed that hyperhomocysteinemia is involved in reducing brain blood flow and producing the depolarization wave defined as cerebral spreading depression (CSD). These facts associated with reduced oxygen transfer could act as trigger of migraine attack. The endothelial damage induced by high levels of homocysteine could decrease nitric oxide release and leads to the initiation and maintenance of migraine attacks [9,12,14,23]. Naturally occurring folate found in food is present in the reduced, polyglutamated form with methyl or formyl as the one carbon substitution. FA found in fortified food and supplements is a synthetic, fully oxidized monoglutamate form of folate and is reduced to tetrahydrofolate prior to its participation in a metabolic reaction. Relative to naturally found folate, FA has a higher bioavailability, which is defined as the proportion of ingested folate that is absorbed and can be used for metabolic processes. Although there is a broad consensus that FA is more bioavailable than naturally found food folate, there are some intervention trials with food that have reported similar improvements in folate status compared with equimolar or small doses of FA from fortified foods or supplements [14,21,22,23]. Previous clinical trials by Lea and Menon [15,22] have provided evidence that homocysteine lowering by FA supplementation can reduce migraine disability, and that this effect may be modified by polymorphisms in genes coding for key enzymes that affect folate metabolism, such as the MTHFR genotype. T allele carriers of the MTHFR C677T genotype with a 35-70% reduction in their enzymatic rate are genetically slower in homocysteine metabolism. The Author demonstrated that an increase in dietary folate, especially the more bioavailable FA consumption levels, may effectively reduce migraine frequency in female migraineurs. If this is a causative relationship, then the T allele carriers of the MTHFR C677T variant may need higher levels of FA compared with CC genotype carriers to experience a significant reduction in their migraine frequency. According to Lea data, we took the dose of vitamins B9(2 mg), B6(25 mg), B12(400 mcg) and our results are good and encourage us to undertake this therapeutic procedure. Our opinion is that the

increase of homocysteine with age in homozygous type unlike heterozygous type and in controls in which this increase is very reduced, represents a very important observation. It occurs, that is, a sort of homocysteine accumulation with age and this affects both the brain and the progression of migraine. The data in paediatric literature are few and there are not longitudinal studies of migraineurs children treated compared to which one non treated. The migraine represent a disease with more comorbidities as cerebrovascular diseases, cognitive disabilities and attention deficit [3,9,19,21,34]. Setting up a therapeutic program must go beyond immediate response to a drug and immediate therapeutic success. Therefore, in the developmental age, the prevention of comorbidities is an important baggage to be dealt with correct.

NOTES

Conflict of Interests

Elisabetta Tozzi, Agnese Onofri, Giulia Iapadre, Martina Mazzilli, Stefano Necozone declare that they have no conflict of interests regarding the publication of this paper.

REFERENCES

1. An XK, Lu CX, Ma QL, Zhang XR, et al (2013). Association of MTHFR C677T Polymorphisms with Susceptibility to Migraine in the Chinese Population. *Neuroscience Letters* 549: 7800-8115. <https://doi.org/10.1016/j.neulet.2013.06.028>
2. Bottini F, Celle ME, Calevo MG, Amato S, et al (2006). Metabolic and Genetic Risk Factors for Migraine in Children. *Cephalalgia* 26: 731-737. <https://doi.org/10.1111/j.1468-2982.2006.01107.x>
3. Clarke R, Bennett D, Parish S, Lewington S, et al (2014). Effects of homocysteine lowering with b vitamins on cognitive aging: Meta-analysis of 11 trials with cognitive data on 22,000 individuals. *Am. J. Clin. Nutr.* 100 (2): 657-666. <https://doi.org/10.3945/ajcn.113.076349>
4. De Laet C, Wautrecht JC, Brasseur D, Dramaix M, et al (1999). Plasma homocysteine concentrations in a Belgian school-age population. *Am J Clin. Nutr.* 69:968-72. <https://doi.org/10.1093/ajcn/69.5.968>.
5. Del Sette M, Dinia L, Bonzano L, Roccatagliata L, et al (2008). White matter lesions in migraine and right-to-left shunt: a conventional and diffusion MRI study. *Cephalalgia* 28: 376-382. <https://doi.org/10.1111/j.1468.2982.2008.01544.x>.
6. Endler G, Kyrle PA, Eichinger S, Exner M, et al (2001). Multiplexed mutagenically separated PCR: simultaneous singletube detection of the factor VR506Q (G1691A), the prothrombin G20210A, and the methylenetetrahydrofolate reductase A223V (C677T) variants. *Clin Chem* 47(2): 333-335.
7. Ferro A, Castro MJ, Lemos C, Santos M, et al (2008). The C677T polymorphism in MTHFR is not associated with migraine in Portugal. *Disease Markers* 25: 107-113. <https://dx.doi.org/10.1155/2008/178679>
8. Ford AH and Almeida OP (2012). Effect of homocysteine lowering treatment on cognitive function: A systematic review and meta-analysis of randomized controlled trials. *J. Alzheimer's Dis.* 29, 133-149. *BioMed Research International* 2015:469529. <https://dx.doi.org/10.1155/2015/469529>
9. Graham IM and Callaghan PO (2002). Vitamins, homocysteine and cardiovascular risk. *Cardiovascular drugs and therapy*, vol. 16, no. 5, pp. 383-389.
10. Herak DC, Antolic MR, Krleza JL, Pavic M, et al (2007). Inherited prothrombotic risk factors in children with stroke, transient ischemic attack, or migraine. *Pediatrics*. 123(4): e653-60. <https://doi.org/10.1542/peds.2007-3737>.
11. International headache society (2013). The international classification of headache disorders, 3rd edition (Beta version) *Cephalalgia* 33: 629-808.
12. Jakubowski H (2006). Pathophysiological consequences of homocystein excess. *The Journal of Nutrition*, vol. 136, no. 6, supplement, pp. 1741S-1749S. <https://doi.org/10.1093/jn/136.6.1741S>
13. Kennedy DO (2016). B Vitamins and the brain: mechanisms, dose and efficacy- A review. *Nutrients* 8(2):68. <https://doi.org/10.3390/nu8020068>.
14. Kowa H, Yasui K, Takeshima T, Urakami K, et al (2000). The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. *Am J Med Genet* 96(6): 762-4.
15. Lea RA, Ovcarić M, Sundholm J, MacMillan J, et al (2004). The Methylenetetrahydrofolate reductase gene variant C677T influences susceptibility to migraine with aura. *BMC Med* 2:3. <https://doi.org/10.1186/1741-7015-2-3>.
16. Liu A †, Menon S †, Colson NJ, Quinlan S, et al (2010). Analysis of the MTHFR C677T variant with

migraine phenotypes. *BMC Research Notes*, 3:213. <https://doi.org/10.1186/1756-0500-3-213>.

17. Lorenz AL, Kahre T, Mihailov E, Nikopensius T, et al (2014). Are Methylenetetrahydrofolate Reductase (MTHFR) Gene Polymorphisms C677T and A1298C Associated with Higher Risk of Pediatric Migraine in Boys and Girls? *J Biomed Sci Eng* 7: 464-472. <http://dx.doi.org/10.4236/jbise.2014.78049>.

18. Maizels M, Blumenfeld A, and Burchette R (2004). A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. *Headache*, vol. 44, no. 9, pp. 885–890.

19. Malouf R, Areosa Sastre A (2003). Vitamin B12 for cognition. *Cochrane Database Syst.Rev*, (3):CD004326.

20. Malouf R, Grimley Evans J (2008). Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. *Cochrane Database Syst.Rev*, (4):CD004514. <https://doi.org/10.1002/14651858.CD004514.pub2>.

21. McCully KS (2007). Homocysteine, vitamins, and vascular disease prevention. *The American Journal of Clinical Nutrition*, vol. 86, no. 5, pp. 1563S–1568S.

22. Menon S, Lea RA, Ingle S (2015). Effects of dietary folate intake on migraine disability and frequency. *Headache* 55: 301-319. <https://doi.org/10.1111/head.12490>

23. Ohrvik VE, Witthoft CM (2011). Human folate bioavailability. *Nutrients*;3(4):475-490. <https://doi.org/10.3390/nu3040475>

24. Oterino A, Valle N, Bravo Y, Munoz P, et al (2004). MTHFR T677 Homozygosis. Influences the Presence of Aura in Migraineurs. *Cephalalgia* 24(6): 491-494. <https://doi.org/10.1111/j.1468-2982.2004.00692.x>

25. Refsum H, Grindflek AW, Ueland PM, Fredriksen A, et al (2004). Screening for serum total homocysteine in newborn children. *ClinChem* 50(10): 1769-1784. <https://doi.org/10.1373/clinchem.2004.036194>

26. Rubino E, Ferrero M, Rainero I, Binello E, et al (2009). Association of the C677T polymorphism in the MTHFR gene with migraine: a meta-analysis. *Cephalalgia* 29(8): 818-825. <https://doi.org/10.1111/j.1468-2982.2007.01400.x>

27. Sadeghi O, Maghsoudi Z, Askari G, Khorvash F, et al (2014). Association between serum levels of homocysteine with characteristics of migraine attacks

in migraine with aura. *J Res Med Sci* 19(11): 1041-1045.

28. Samaan Z, Gaysina D, Cohen-Woods S, Craddock N, et al (2011). Methylenetetrahydrofolate Reductase Gene Variant (MTHFR C677T) and Migraine: A Case Control Study and Meta-analysis. *BMC Neurology*, 11:66. <https://doi.org/10.1186/1471-2377-11-66>.

29. Schoenen J, Jacquy J, and Lenaerts M (1998). Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial. *Neurology*, vol. 50, no. 2, pp. 466–470.

30. Shaik MM, Lin TH, Kamal MA, and Gan SH (2014). Do folate, vitamins B6 and B12 play a role in the pathogenesis of migraine? The role of pharmacoeugenomics. *CNS & Neurological Disorders-Drug Targets*, vol. 13, no. 5, pp. 828–835.

31. Shaik MM and Gan SH (2015). Vitamin supplementation as possible prophylactic treatment against migraine with aura and menstrual migraine. *Bio med Res Int*. <https://doi.org/10.1155/2015/469529>

32. Tozzi E, Piccorossi A, Gammella C, Onofri A et al (2017). The Headaches and Polymorphisms of the Methylenetetrahydrofolate Reductase. *J Headache Pain Manag* 2:12. <https://doi.org/10.4172/2472-1913.100042>

33. Vollset SE, Refsum H and Ueland PM (2001). Population determinants of homocysteine. *The American Journal of Clinical Nutrition*, vol. 73, no. 3, pp. 499–500. <https://doi.org/10.1093/ajcn/73.3.499>

34. Wald DS, Kasturiratne A, Simmonds M (2010). Effect of folic acid, with or without other B vitamins, on cognitive decline: Meta-analysis of randomized trials. *Am J Med*, 123(6), 522–529. <https://doi.org/10.1016/j.amjmed.2010.01.017>.